• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
Fat Tail Daily

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
  • Subscribe
Home | MGC Pharmaceuticals Share Price Flat After Spike Following Trial Results

MGC Pharmaceuticals Share Price Flat After Spike Following Trial Results

By Lachlann Tierney, December 15, 2020

ASX MXC Share Price - MGC Pharmaceuticals Share Price
At the time of writing, the share price of MGC Pharmaceuticals Ltd [ASX:MXC] is flat, trading at 3.2 cents a share. After a slide that persisted through to December, the MXC share price subsequently rose sharply this month...

At the time of writing, the share price of MGC Pharmaceuticals Ltd [ASX:MXC] is flat, trading at 3.2 cents a share.

After a slide that persisted through to December, the MXC share price subsequently rose sharply this month:

ASX MXC Share Price Chart - MGC Pharmaceuticals

Source: TradingView

Let’s look at the details of its phase two trial results for its product, ArtemiCTM.

Successful trial leads to spike in MXC share price

In early trading, the MXC share price went as high as 4.2 cents but later settled flat.

Here are the key details from today’s announcement:

‘● Full results of MGC Pharma’s phase II double blind clinical trial show ArtemiCTM has successfully met the primary and secondary study endpoints

‘● ArtemiCTM statistically significantly improved the clinical recovery of 50 COVID-19 infected patients in the treatment group in comparison with placebo

‘● 100% of the patients in the treatment group met the Trial’s primary end point and fully recovered within 15 days of follow up

‘● ArtemiCTM delivered a NEWS score (main parameter of clinical improvement in COVID-19 patients) of less than or equal to 2 in 100% of patients in the treatment group…

‘● Next steps for the product development will include immediate evaluation of a Phase III Trial in COVID-19 and flu patients and classification of ArtemiC™ under new name as IMP (Investigational Medicinal Product) which will be produced in MGC EU GMP facilities

‘● Following successful Phase III Trial results ArtemiCTM can be produced and sold by the Company as a supplement, through its existing production facilities and distribution networks’

There’s plenty to digest in the announcement, but the main punchline is that phase two results demonstrate efficacy as an anti-inflammatory treatment for COVID-19.

Outlook for MXC share price

MGC Pharma has other products in the pipeline for a range of diseases.

It was a difficult year for a number of pot stocks, but a number of companies are starting to show signs of life.

However, the fact that today’s early spike in the MXC share price fell flat means a number of investors may have taken the opportunity to exit on a high note.

Regards,

Lachlann Tierney,

For Money Morning

 

PS: If you want to learn how to trade a volatile stock like MXC, you can grab a free copy of Murray Dawes’ latest technical analysis report right here. Murray shows you what to look for in a chart, and it’s a great read if you want to wrap your head around risk.

Bio Tech Latest ASX News Small Caps Stocks and Bonds

Primary Sidebar

Latest Articles

  • Exploring the Net Zero Challenge: Interview with Nigel Farage
  • Stocks to Buy if Rates Have Peaked
  • Don’t Trust This Bullshit Rally | What’s Not Priced In
  • Hidden Megatrends — Investing in the $21 Trillion Grid Overhaul
  • Boss Energy [ASX:BOE] Reveals Takeover Target

Footer

YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2023 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988